Fig. 2

Post-recurrence survival (PRS) for each intrinsic subtype and for pathological response. Although TNBC was associated with the worst prognosis, PRS was not significantly different in each subtype (p = 0.396, log-rank) (a). Patients who achieved pCR had significantly better PRS among all breast cancers (p = 0.021, log-rank) (b). Patients who achieved pCR had significantly better PRS of Luminal breast cancer (p = 0.031, log-rank) (c). PRS was not significantly differ between patients with pCR and non-pCR of TNBC (p = 0.329, log-rank) (d)